Amylin Analog

99.4%

Purity

MOQ

Contact for MOQ

Lead Time

3~5 day

Storage

-20°C

Factory direct peptide supply

Cagrilintide

Long-acting Amylin Analog

99%+HPLC purity options

COABatch documents

3-5DFast preparation

Cagrilintide is a long-acting amylin analog that acts as a non-selective amylin receptor agonist. It regulates satiety, delays gastric emptying, and has demonstrated significant efficacy in metabolic research. It shows particularly powerful synergistic effects when combined with GLP-1 receptor agonists like semaglutide.

Key Benefits

Modulates satiety and food intake pathways

Delays gastric emptying in research models

Synergistic weight reduction with GLP-1 agonists

Extended half-life suitable for weekly dosing

Available Sizes

Selected: 5 mg/vial (10 vials)

Contact for pricing

Ready for quotation Contact us and send this product name.

Inquiry message Send inquiry / request COA

For faster quotation, include purity, quantity, packaging request and target market.

Product Description

CAS Number

1415456-99-3

Appearance

White to off-white lyophilized powder

Solubility

Soluble in water at ≥1 mg/mL

Storage

-20°C for long-term; 4°C for up to 4 weeks

Amino Acid Sequence

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH₂

Molecular Information

Molecular FormulaC₁₇₄H₂₈₀N₄₆O₅₆S₂

Molecular Weight3952.47 Da

Purity MethodHPLC & MS

Technical Specifications

Product NameCagrilintide

Alias / Trade NameLong-acting Amylin Analog

CAS Number1415456-99-3

Molecular FormulaC₁₇₄H₂₈₀N₄₆O₅₆S₂

Molecular Weight3952.47 Da

Purity99.4% (by HPLC & MS)

AppearanceWhite to off-white lyophilized powder

SolubilitySoluble in water at ≥1 mg/mL

Storage Conditions-20°C for long-term; 4°C for up to 4 weeks

Salt FormAcetate

Minimum Order QuantityContact for MOQ

Available Sizes5 mg/vial, 10 mg/vial

Amino Acid Sequence

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH₂ (Disulfide bridge: Cys2-Cys7)

Certificate of Analysis

Batch-specific testing results

Note: A batch-specific Certificate of Analysis (COA) is provided with every order. Contact us to request a sample COA for this product.

Factory supply workflow

From product name to confirmed quotation.

Send the product name, selected strength, quantity, purity requirement, packaging style and destination market. The sales team can confirm stock, MOQ, batch COA, HPLC/MS files, lead time and private label options.

01Confirm product

Product name, mg/vial, vial count and target quantity.

02Verify documents

Batch COA, HPLC, MS, appearance and storage conditions.

03Quote & packaging

Factory price, MOQ, label, box and custom brand support.

04Dispatch

Fast preparation with export support and shipment updates.

Related Research

Peer-reviewed scientific literature on Cagrilintide from PubMed, NEJM, The Lancet, and other authoritative sources.

Phase II2021

Cagrilintide research in body-weight and metabolic study populations

Lau DCW, et al.

The Lancet, 398: 2160–2172 (2021)

Key Finding

Cagrilintide treatment resulted in significant dose-dependent weight loss compared to placebo, with the 4.5 mg dose leading to a mean weight reduction of 10.8% at 26 weeks.

DOI: 10.1016/S0140-6736(21)01751-7 PubMed: 34788595

Phase Ib2021

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg

Enebo SR, et al.

The Lancet, 397: 1736–1748 (2021)

Key Finding

The combination of cagrilintide and semaglutide 2.4 mg was well tolerated and produced greater weight loss (17.1% at 20 weeks) than semaglutide alone (9.8%), demonstrating a powerful synergistic effect.

DOI: 10.1016/S0140-6736(21)00845-X PubMed: 33894838